Showing results (31-40 of 62) with videos related to

Sort By:
Pageof 7
Mabs|February 12, 2016
Anti-tumoral, anti-angiogenic and anti-metastatic efficacy of a tetravalent bispecific antibody (TAvi6) targeting VEGF-A and angiopoietin-2Werner Scheuer, Markus Thomas, Petra Hanke, et al.
Antibodies (Basel, Switzerland)|November 24, 2025
CEA-4-1BBL: CEACAM5-Targeted 4-1BB Ligand Fusion Proteins for Cis Co-Stimulation with CEA-TCBChristina Claus, Claudia Ferrara-Koller, Johannes Sam, et al.
Journal for Immunotherapy of Cancer|April 15, 2026
Precision modeling of tumor antigen-specific T-cell responses in humanized mice for preclinical assessment of cancer immunotherapiesSamuel Gebhardt, Marine Le Clech, Barbara Höllbacher, et al.
Nano Letters|January 23, 2009
Nanoscale oxidative patterning of metallic surfaces to modulate cell activity and fateFiorenzo Vetrone, Fabio Variola, Paulo Tambasco de Oliveira, et al.
Pharmaceutics|December 28, 2021
Pharmacokinetics and Pharmacodynamics of T-Cell Bispecifics in the Tumour Interstitial FluidMiro Julian Eigenmann, Tine Veronica Karlsen, Marek Wagner, et al.
Journal for Immunotherapy of Cancer|July 30, 2021
Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodiesGabrielle Leclercq, Hélène Haegel, Anneliese Schneider, et al.
Oncoimmunology|September 2, 2025
Chronic antigen stimulation in melanoma induces T cell exhaustion and limits efficacy of T cell bispecific therapiesIdil Hutter-Karakoc, Eleni Maria Varypataki, Aparna Neelakandhan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 28, 2016
In Vivo Fluorescence Imaging of the Activity of CEA TCB, a Novel T-Cell Bispecific Antibody, Reveals Highly Specific Tumor Targeting and Fast Induction of T-Cell-Mediated Tumor KillingSteffi Lehmann, Ramanil Perera, Hans-Peter Grimm, et al.
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz|May 16, 2024
[Automated surveillance and risk prediction with the aim of risk-stratified infection control and prevention (RISK PRINCIPE)]Michael Marschollek, Mike Marquet, Nicolás Reinoso Schiller, et al.
Frontiers in Oncology|February 22, 2021
Corrigendum: Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor ActivityJohannes Sam, Sara Colombetti, Tanja Fauti, et al.
Pageof 7